Retension Pharma director Franklin M. Berger acquires 10,000 common shares for $120,000
RTSN•Director Franklin M. Berger acquired 10,000 Retension Pharmaceuticals common shares for $120,000, held indirectly through FMB Research. He also converted into 12,517 common shares.
1. Share transactions
Franklin M. Berger increased his exposure to Retension Pharmaceuticals through a conversion into 12,517 common shares and a separate purchase of 10,000 shares at $12 each. The purchase was held indirectly through FMB Research.
